Want to pursue science and maximize social impact? Unsure what opportunities exist outside of Academia? Join the Stanford Biotechnology Group (Website:
stanfordbiotechgroup.com; Twitter @stanfordbiotech) on Monday February 22nd at 5:30pm PT for a chat with Ethan Perlstein, CEO of Perlara PBC (
https://www.perlara.com/)! As the first biotechnology public benefit corporation, Perlara has been at the nexus of pre-clinical, clinical, and business model innovation.
You will receive the Zoom link the day before the event.
Dr. Ethan Perlstein is a biotech entrepreneur/company builder, solo VC and evolutionary pharmacologist. He is the founder and CEO of Perlara PBC, the first public-benefit corporation dedicated to developing drugs for rare genetic diseases. Perlara leverages simple, genetically defined biological models to identify drugs that modify rare diseases and works to incorporate patient families into the drug development process. Prior to launching Perlara, Ethan held an independent postdoctoral fellow position at the Lewis-Sigler Institute of Princeton after completing his PhD at Harvard with Stuart Schreiber.